Introduction {#Sec1}
============

Recent improvements in perinatal and neonatal intensive care have resulted in the improved survival of periviable, extremely preterm (EPT) infants^[@CR1]--[@CR4]^. However, EPT birth still remains a major cause of infant mortality and morbidity in survivors^[@CR5]^. For this reason, there are concerns that the improved survival of EPT infants might be accompanied by increases in disabling morbidity in survivors^[@CR6],[@CR7]^. In contrast, recent studies have reported that the improved survival of EPT infants has been accompanied by significantly increased survival without major morbidities, especially in more mature EPT infants^[@CR8],[@CR9]^. Overall, the available data regarding the effects of the improved survival of EPT infants on morbidity among survivors remain largely controversial, and further studies are needed to clarify the issue.

In our previous single-centre studies, we observed that significantly improved survival of EPT infants with 23--24 weeks' gestation was accompanied by a significantly reduced incidence of bronchopulmonary dysplasia (BPD) and nosocomial sepsis in more mature EPT infants with 25--26 weeks' gestation^[@CR10],[@CR11]^. However, as these studies reflect the experience of a single centre, the evidence is still very limited. Therefore, larger nationwide neonatal network data would be necessary to allow concrete conclusions to be drawn about the effects of the improved survival of EPT infants on major morbidity in survivors. The Korean Neonatal Network (KNN) is a nationwide, multicentre, prospective, web-based cohort registry system for very low birth weight infants (VLBWIs) with a birth weight \<1,500 g^[@CR12]^. In our previous study using the KNN data, we observed wide inter-hospital variations in the mortality rate of infants with 23--24 weeks' gestation and evidence-based perinatal and neonatal management, including antenatal steroid use and better delivery room care, contributed to the enhanced survival of these EPT infants close to the limit of viability^[@CR13]^. With the above in mind, we aimed to determine whether the improved survival of infants with 23--24 weeks' gestation is associated with less major morbidity and more survival without major morbidities in more mature infants with 25--26 weeks' gestation.

Results {#Sec2}
=======

Demographic and perinatal characteristics {#Sec3}
-----------------------------------------

According to the data of the National Statistical Office, the number of 23--26-week infants born in Korea in 2013--2016 was 3,005. In this study, 2,184 infants at 23--26 weeks were registered^[@CR14]^. Table [1](#Tab1){ref-type="table"} shows a comparison of demographic and perinatal characteristics of the infants born at 23--24 weeks' and 25--26 weeks' gestation between the two study groups. In the overall group (infants with 23--26 weeks' gestation), gestational age, birth weight, and caesarean section rate were significantly lower and antenatal steroid use, histologic chorioamnionitis, and *in vitro* fertilisation rates were significantly higher in group 1 compared to group 2. In infants with 23--24 weeks' but not in those with 25--26 weeks' gestation, the Apgar score at 1 and 5 min was significantly higher in group 1 than those in group 2. There were 68 births outside of hospital, 33/1074 (3.1%) babies were born outside of hospital in group 1 and 35/1009 (3.5%) babies were born outside of hospital in group 2. There were no significant differences in 23--24 weeks' gestation in the 15/398 (3.8%) infants at 23--24 week' gestation in group 1 and 9/322 (2.8%) infants in group 2.Table 1Comparison of perinatal and demographic characteristics between the two groups.CharacteristicsGA 23--24 Wn = 720*p*-valueGA 25--26 Wn = 1,363*p*-valueGA 23--26 Wn = 2,083*p*-valueGroup 1 (n = 398)Group 2 (n = 322)Group 1 (n = 676)Group 2 (n = 687)Group 1 (n = 1,074)Group 2 (n = 1,009)Gestational age (weeks)23.6 ± 0.523.6 ± 0.50.79325.5 ± 0.525.6 ± 0.50.12724.8 ± 1.024.9 ± 1.00.007Birth weight (g)656.6 ± 107.5656 ± 105.40.979833.1 ± 160.5843.3 ± 151.70.227767.7 ± 166.6783.8 ± 163.60.026Apgar score, 1 min2.9 ± 1.62.6 ± 1.60.0253.7 ± 1.73.6 ± 1.80.8913.4 ± 1.73.3 ± 1.80.435Apgar score, 5 min5.3 ± 2.04.9 ± 2.00.0156.1 ± 1.86.0 ± 1.80.2375.8 ± 1.95.7 ± 2.00.076Hospital days (survival)127.8 ± 40.4133.8 ± 54.30.326103.9 ± 37.1106.5 ± 41.10.275111.5 ± 39.7111.2 ± 44.70.865Body temperature (°C)35.8 ± 0.935.6 ± 0.90.10936.0 ± 0.636.0 ± 0.70.30535.9 ± 0.835.9 ± 0.80.206Male, n (%)199 (50.0)164 (50.9)0.804315 (46.6)325 (47.3)0.793560 (52.1)520 (51.5)0.782Antenatal steroid use, n (%)323 (81.2)214 (66.5)\<0.001561 (83.0)531 (77.3)0.008884 (82.3)745 (73.8)\<0.001Caesarean section, n (%)235 (59.0)196 (60.9)0.620482 (71.3)524 (76.3)0.037717 (66.8)720 (71.4)0.023PROM, n (%)203 (51.0)171 (53.1)0.575275 (40.7)315 (45.9)0.054478 (44.5)486 (48.2)0.094Histologic chorioamnionitis, n (%)228 (57.3)124 (38.5)\<0.001308 (45.6)234 (34.1)\<0.001536 (49.9)358 (35.5)\<0.001HDP (%)15 (3.8)20 (6.2)0.13080 (11.8)55 (8.0)0.01894 (8.8)75 (7.4)0.239*In vitro* fertilisation, n (%)115 (28.9)79 (24.5)0.190166 (24.6)122 (17.8)0.002281 (26.2)201 (19.9)\<0.001Values are expressed as mean ± standard deviation or number (%).GA, gestational age; HDP, hypertensive disorder of pregnancy; PROM, premature rupture of membranes; W, weeks.

Mortality and morbidity {#Sec4}
-----------------------

Table [2](#Tab2){ref-type="table"} shows the mortality, composite morbidity, and survival without major morbidities of infants in the two study groups. The overall and gestational age-specific mortality rates in group 1 were all significantly lower than those in group 2. In the infants with 25--26 weeks' but not 23--24 weeks' gestation, the survival without major morbidities rate was significantly higher and the incidence of BPD and periventricular leukomalacia (PVL) were significantly lower in group 1 than in group 2. The overall incidence of late-onset sepsis (LOS) in the infants with 23--26 weeks' gestation was significantly lower in group 1 than in group 2. The overall incidence of ROP in infants with 23--26 weeks' gestation was significantly higher in group 1 than in group 2 (p = 0.001).Table 2Comparison of mortality, morbidity, and survival without major morbidities rate between the two groups.(%)GA 23--24 Wn = 720*p*-valueGA 25--26 Wn = 1,363*p*-valueGA 23--26 Wn = 2,083*p*-valueGroup 1\
(n = 398)Group 2\
(n = 322)Group 1\
(n = 676)Group 2\
(n = 687)Group 1\
(n = 1,074)Group 2\
(n = 1,009)Mortality\*130 (32.7)225 (69.9)\<0.001105 (15.5)211 (30.7)\<0.001235 (21.9)436 (43.2)\<0.001SWMM19 (7.1)8 (8.2)0.709178 (31.2)88 (18.5)\<0.001197 (23.5)96 (16.8)0.002BPD194 (72.4)70 (72.2)0.966269 (47.1)301 (63.2)\<0.001463 (55.2)371 (64.7)\<0.001IVH64 (23.9)29 (29.9)0.24562 (10.9)66 (13.9)0.140126 (15.0)95 (16.6)0.428PVL45 (16.8)9 (9.3)0.07852 (9.1)68 (14.3)0.00997 (11.6)77 (13.4)0.293NEC48 (17.9)11 (11.3)0.13262 (10.9)66 (13.9)0.13993 (11.1)59 (10.3)0.639ROP163 (60.8)54 (55.7)0.064190 (33.3)146 (30.7)0.208353 (42.1)200 (34.9)0.001LOS84 (31.3)45 (46.4)0.008125 (21.9)157 (33.0)\<0.001209 (24.9)202 (35.3)\<0.001SWMM, survival without major morbidities at discharge; BPD, bronchopulmonary dysplasia ≥ moderate; GA, gestational age; IVH, intraventricular haemorrhage grade 3 or 4; LOS, late-onset neonatal sepsis; NEC, necrotizing enterocolitis stage ≥2; PVL, periventricular leukomalacia; ROP, retinopathy of prematurity stage ≥3; W: weeks.\*Percentages for morbidities refer to survival.

Clinical factors associated with mortality and survival without major morbidities {#Sec5}
---------------------------------------------------------------------------------

Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} shows the results of the multiple logistic regression analysis of the clinical factors associated with mortality and clinical factors associated with survival without major morbidities stratified by gestational age group, respectively. Adjusted variables were gestational age, birth weight (100 g increments), Apgar score at 5 min, antenatal steroid use, delivery mode, and histologic chorioamnionitis.Table 3Multiple logistic regression analysis of the clinical factors associated with mortality stratified by gestational age group.GROUP 1GA 23--24 W*p*-valueGA 25--26 W*p*-valueTotal*p*-valueAdjusted OR (95% CI)Adjusted OR (95% CI)Adjusted OR (95% CI)Gestational age (weeks)0.830 (0.519--1.329)0.4380.985 (0.647--1.499)0.9420.801 (0.662--0.970)0.023Birth weight (per 100 g)0.751 (0.592--0.952)0.0180.841 (0.724--0.978)0.0240.805 (0.710--0.912)0.001Apgar score, 5 min0.959 (0.850--1.081)0.4890.804 (0.711--0.908)\<0.0010.876 (0.805--0.954)0.002Body temperature0.780 (0.604--1.008)0.0570.752 (0.536--1.055)0.0990.770 (0.629--0.944)0.012Antenatal steroid use0.548 (0.303--0.992)0.0470.879 (0.484--1.595)0.6710.702 (0.466--1.056)0.089Caesarean section0.721 (0.450--1.154)0.1730.834 (0.504--1.380)0.4800.757 (0.540--1.062)0.107Chorioamnionitis0.893 (0.559--1.426)0.6350.599 (0.373--0.959)0.0330.750 (0.541--1.038)0.083**GROUP 2GA 23--24** **W*p*** **-valueGA 25--26** **W*p*** **-valueTotal*p*** **-value**Gestational age (weeks)0.392 (0.216--0.711)0.0020.625 (0.450--0.867)0.0050.535 (0.446--0.643)\<0.001Birth weight (per 100 g)0.677 (0.501--0.914)0.0110.772 (0.679--0.877)\<0.0010.757 (0.673--0.851)\<0.001Apgar score, 5 min1.015 (0.874--1.178)0.8480.984 (0.894--1.083)0.7370.988 (0.913--1.070)0.769Body temperature0.926 (0.663--1.293)0.6510.961 (0.732--1.260)0.7720.936 (0.761--1.152)0.535Antenatal steroid use1.168 (0.634--2.151)0.6180.750 (0.490--1.149)0.1860.850 (0.599--1.206)0.362Caesarean section1.276 (0.727--2.238)0.3961.251 (0.816--1.919)0.3041.247 (0.891--1.746)0.198Chorioamnionitis0.942 (0.543--1.636)0.8330.675 (0.463--0.985)0.0410.743 (0.547--1.008)0.057**TOTALGA 23--24** **W*p*** **-valueGA 25--26** **W*p*** **-valueTotal*p*** **-value**Gestational age (weeks)0.661 (0.471--0.927)0.0160.777 (0.605--0.999)0.0490.682 (0.602--0.773)\<0.001Birth weight (per 100 g)0.757 (0.637--0.901)0.0020.827 (0.753--0.908)\<0.0010.807 (0.743--0.876)\<0.001Apgar score, 5 min0.967 (0.888--1.054)0.4490.904 (0.841--0.973)0.0070.929 (0.878--0.982)0.009Body temperature0.841 (0.693--1.019)0.0770.831 (0.676--1.021)0.0770.835 (0.726--0.961)0.012Antenatal steroid use0.609 (0.409--0.906)0.0150.789 (0.564--1.103)0.1660.704 (0.547--0.906)0.007Caesarean section1.011 (0.722--1.415)0.9511.108 (0.805--1.524)0.5291.045 (0.831--1.313)0.708Chorioamnionitis0.687 (0.497--0.948)0.0220.604 (0.454--0.804)0.0010.639 (0.517--0.790)\<0.001CI, confidence interval; GA, gestational age; OR, odds ratio; W, weeks.Table 4Multiple logistic regression analysis of the clinical factors associated with survival without major morbidities stratified by gestational age group.GROUP 1GA 23--24 W*p*-valueGA 25--26 W*p*-valueTotal*p*-valueAdjusted OR (95% CI)Adjusted OR (95% CI)Adjusted OR (95% CI)Gestational age (weeks)1.763 (0.651--4.774)0.2641.591 (1.136--2.229)0.0071.895 (1.511--2.375)\<0.001Birth weight (per 100 g)1.056 (0.676--1.649)0.8111.224 (1.078--1.389)0.0021.220 (1.080--1.378)0.001Apgar score, 5 min1.275 (0.996--1.632)0.0541.292 (1.157--1.442)\<0.0011.293 (1.169--1.431)\<0.001Body temperature1.070 (0.612--1.870)0.8131.041 (0.772--1.402)0.7931.047 (0.806--1.359)0.733Antenatal steroid use1.023 (0.283--3.702)0.7931.016 (0.625--1.651)0.9501.001 (0.636--1.575)0.996Caesarean section5.108 (1.474--17.706)0.0101.337 (0.899--1.987)0.1521.598 (1.106--2.308)0.012Chorioamnionitis1.074 (0.462--2.501)0.8681.244 (0.871--1.776)0.2301.223 (0.880--1.699)0.231**GROUP 2GA 23--24** **W*p*** **-valueGA 25--26** **W*p*** **-valueTotal*p*** **-value**Gestational age (weeks)2.890 (0.740--11.279)0.1272.216 (1.424--3.448)\<0.0011.945 (1.432--2.641)\<0.001Birth weight (per 100 g)1.263 (0.692--2.307)0.4471.195 (1.017--1.406)0.0311.201 (1.027--1.404)0.022Apgar score, 5 min0.758 (0.548--1.047)0.0931.071 (0.947--1.210)0.2751.018 (0.911--1.138)0.752Body temperature1.321 (0.604--2.889)0.4861.536 (1.066--2.212)0.0211.454 (1.044--2.027)0.027Antenatal steroid use0.654 (0.187--2.282)0.5051.304 (0.745--2.280)0.3531.164 (0.703--1.925)0.555Caesarean section0.813 (0.246--2.687)0.7341.010 (0.617--1.6510.9700.965 (0.614--1.516)0.877Chorioamnionitis1.047 (0.325--3.369)0.9390.831 (0.527--1.312)0.4270.876 (0.575--1.334)0.537**TOTALGA 23--24** **W*p*** **-valueGA 25--26** **W*p*** **-valueTotal*p*** **-value**Gestational age (weeks)2.019 (0.916--4.446)0.0811.739 (1.340--2.256)\<0.0011.845 (1.545--2.204)\<0.001Birth weight (per 100 g)1.134 (0.796--1.616)0.4851.191 (1.081--1.312)\<0.0011.190 (1.084--1.306)\<0.001Apgar score, 5 min1.070 (0.890--1.287)0.4701.194 (1.102--1.294)\<0.0011.174 (1.091--1.264)\<0.001Body temperature1.107 (0.720--1.703)0.6431.223 (0.980--1.527)0.0751.193 (0.978--1.455)0.081Antenatal steroid use0.831 (0.359--1.923)0.6651.184 (0.829--1.690)0.3531.122 (0.808--1.558)0.490Caesarean section2.313 (1.025--5.218)0.0431.134 (0.839--1.533)0.4141.250 (0.945--1.654)0.119Chorioamnionitis1.192 (0.611--2.326)0.6061.177 (0.899--1.542)0.2361.184 (0.923--1.521)0.184CI, confidence interval; GA, gestational age; OR, odds ratio; W, weeks.

In the infants with 23--24 weeks' gestation, birth weight in both groups 1 and 2, antenatal steroid use in group 1 but not 2, and gestational age in group 2 but not 1 were clinical factors significantly associated with lower mortality (Table [3](#Tab3){ref-type="table"}). In infants with 25--26 weeks' gestation, birth weight and chorioamnionitis in groups 1 and 2 and Apgar score at 5 min in group 1 but not 2 were clinical factors associated with mortality.

In infants with 23--24 weeks' gestation, caesarean section was associated with survival without major morbidities at discharge only in group 1 (Table [4](#Tab4){ref-type="table"}). In the infants with 25--26 weeks' gestation, gestational age and birth weight in both groups 1 and 2, Apgar score at 5 min in group 1 but not 2, and body temperature at admission in group 2 but not 1 were clinical factors significantly associated with survival without major morbidities.

Table [5](#Tab5){ref-type="table"} shows the adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for mortality, survival without major morbidities at discharge, and each morbidity in group 1 versus group 2 with adjustment by multivariate logistic regression. In multiple logistic regression, significantly different clinical factors associated with mortality and survival without morbidities between group 1 and group 2 and previously known factors were adjusted. Therefore, we have chosen the clinical factors which were significantly different at least in 2 GA subgroups from Table [1](#Tab1){ref-type="table"}. The adjusted variables were gestational age, birth weight (100 g increments), Apgar score at 5 min, antenatal steroid use, delivery mode, histologic chorioamnionitis, and *in vitro* fertilisation. In the infants with 23--24 weeks' gestation, the OR of mortality was significantly increased and the incidence of PVL was significantly decreased in group 2 compared to group 1. In the infants with 25--26 weeks' gestation, the ORs of mortality, BPD, intraventricular haemorrhage grade 3 or 4 (severe IVH), PVL, and LOS significantly increased and the OR of survival without major morbidities at discharge were significantly decreased in group 2 than in group 1.Table 5Adjusted odds ratios for mortality, morbidity, and survival without major morbidities according to group stratified by gestational age.SubgroupsGA 23--24 W*p*-valueGA 25--26 W*p*-valueTotal*p*-valueAdjusted OR (95% CI)Adjusted OR (95% CI)Adjusted OR\* (95% CI)Mortality5.276 (3.724--73475)\<0.0012.456 (1.866--3.233)\<0.0013.326 (2.684--4.120)\<0.001Survival without major morbidities at discharge0.613 (0.307--1.225)0.1660.421 (0.321--0.553)\<0.0010.456 (0.354--0.587)\<0.001BPD1.165 (0.679--1.997)0.5792.244 (1.728--2.915)\<0.0011.984 (1.566--2.512)\<0.001IVH1.385 (0.980--1.959)0.0651.483 (1.103--1.994)0.0091.444 (1.155--1.807)0.001PVL0.522 (0.308--0.883)0.0151.610 (1.137--2.279)0.0071.121 (0.848--1.482)0.423NEC0.672 (0.443--1.019)0.0621.277 (0.907--1.796)0.1610.992 (0.765--1.286)0.950ROP0.729 (0.459--1.157)0.1790.924 (0.703--1.214)0.5710.876 (0.694--1.107)0.267LOS1.091 (0.790--1.507)0.5961.407 (1.103--1.795)0.0061.268 (1.045--1.538)0.016BPD, bronchopulmonary dysplasia moderate or severe; CI, confidence interval; GA, gestational age; IVH, intraventricular haemorrhage grade 3 or 4; LOS, late-onset neonatal sepsis; NEC, necrotising enterocolitis stage ≥2; PVL, periventricular leukomalacia; ROP, retinopathy of prematurity stage 3 or 4; OR, odds ratio; W, weeks.\*The odds ratios correspond to group 2 vs. group 1. Values are adjusted by gestational age, birth weight per 100 g, Apgar score 5 min, antenatal steroid use, delivery mode, histologic chorioamnionitis, and *in vitro* fertilisation.

Discussion {#Sec6}
==========

Besides improving mortality, increasing survival without major morbidities in periviable EPT infants is another important goal of neonatal intensive care. In a previous study, we reported that despite marked immaturity itself, the limit of viability in periviable EPT infants with 23--24 weeks' gestation was not static and could thus be much improved by providing evidence-based perinatal and neonatal intensive care besides active treatment policies^[@CR10],[@CR11],[@CR15]^. In the present study, the survival rate of EPT infants born at 23--26 weeks' gestation was significantly higher in group 1 than in group 2, especially in the infants with 23--24 weeks' gestation. This improved survival rate of EPT infants with 23--24 weeks' gestation was accompanied by significantly lower morbidity (including BPD, severe IVH, PVL, and LOS) and resultant higher survival without major morbidities rates in more mature infants with 25--26 weeks' gestation but not those with 23--24 weeks' gestation. In concordance with our data, Yonge *et al*.^[@CR2]^ reported that significantly reduced mortality in infants with 22--24 weeks' gestation during the last decade in the NICHD NRN data was associated with a significantly improved rate of survival without neurodevelopmental impairment at 18--22 months of corrected age. Stoll *et al*.^[@CR1]^ also showed that improved survival of infants with 23--24 weeks' gestation during the last two decades in the NICHD NRN data was accompanied by survival without major morbidities in more mature infants with 25--28 weeks' gestation. Overall, these findings suggest that evidence-based perinatal and neonatal clinical practices contributing to the decreased mortality rate of most immature infants born at 23--24 weeks' gestation simultaneously contribute to improving survival without major morbidities in more mature EPT infants with 25--26 weeks' gestation. As a result, considerably more EPT infants could enjoy potentially better clinical outcomes and quality of life^[@CR16]^.

Identifying the clinical factors associated with mortality and survival without major morbidities is essential for developing new and effective clinical strategies, not only to overcome the limit of viability but also to improve the quality of life in periviable EPT infants^[@CR3]^. In our previous studies, antenatal steroid use, Apgar score at 5 min, and body temperature at admission were significantly associated with decreased mortality in EPT infants^[@CR15],[@CR17]^. In our previous study, Apgar score at 5 min and lower serum albumin level were the most effective universal predictors of mortality regardless of gestational age within postnatal day 7 (primarily due to pulmonary causes) and after postnatal day 7 (primarily due to capillary leak)^[@CR18]^. In the present study, antenatal steroid use and Apgar score at 5 min in group 1 but not in group 2 were clinical factors associated with mortality in infants with 23--24 and 25--26 weeks' gestation, respectively. For survival without major morbidities, Apgar score at 5 min in group 1 and body temperature at admission to the neonatal intensive care unit (NICU) in group 2 were clinical factors associated with survival without major morbidities in infants with 25--26 weeks' gestation. Collectively, these findings suggest that applying evidence-based perinatal and neonatal intensive care practices, such as antenatal steroid use, better delivery room care including seamless resuscitation conducted by a well-experienced and skilful neonatologist, prevention of heat loss, better early admission care, and prevention of nosocomial sepsis, would be effective not only for improving the survival of periviable infants but also for simultaneously reducing major morbidities, thus increasing survival without major morbidities in the more mature EPT infants.

In the present study, significantly increased survival without major morbidities was achieved by significantly reduced morbidities (such as BPD, severe IVH, PVL, and LOS). Significantly reducing the incidence of severe IVH and PVL might contribute to reduced neurodevelopmental impairments^[@CR1],[@CR2]^. In accordance with the present data, we previously observed that improved survival in infants with 23--24 weeks gestation was associated with the significantly reduced incidence of BPD and nosocomial sepsis^[@CR10],[@CR11]^. However, in contrast, Stoll *et al*.^[@CR1]^ reported that while major morbidities, including LOS, were significantly reduced for infants with 25--28 weeks' gestation with improved survival of infants born at 23--24 weeks, the incidence of BPD was increased. Although few effective treatments are clinically available for treating BPD, wide variability in BPD occurrence across hospitals and some success in reducing the BPD incidence rate within individual hospitals through quality improvement efforts suggests that the identification and implementation of specific neonatal intensive care practices could modify the incidence of morbidities such as BPD^[@CR19],[@CR20]^. In our previous studies, clinical implementation of a less invasive ventilation strategy, including early continuous positive airway pressure after early extubation and less use of oxygen, was effective for reducing not only LOS but also other major morbidities associated with extreme prematurity, such as BPD^[@CR10],[@CR11]^. Taken together, these findings suggest that although it might be difficult to identify which specific clinical strategy plays a pivotal role, quality improvements through evidence-based perinatal and neonatal care practices as a whole can be quite effective for reducing the incidence of major morbidities, thereby increasing survival without major morbidities especially in the more mature infants with 25--26 weeks' gestation, which is accompanied by the improved survival of the infants with 23--24 weeks' gestation. Contrary to this, the overall incidence of ROP in infants with 23--26 weeks' gestation was significantly higher in group 1 than in group 2. Increased incidence of ROP in the higher surviving group of VLBWI was due to competing outcomes, and further studies are necessary to clarify multiple factors associated with ROP.

The limitations of the present study include its retrospective and uncontrolled observational study design on prospectively collected nationwide cohort data. Furthermore, although our data are representative nationwide, including all tertiary NICUs in Korea, the temporal profile of the changes in the association between mortality and survival without major morbidities could not be analysed in this study because data were collected over a short time period. Lack of long-term follow-up outcome data is another limitation of this study. Although study group according to the mortality rate of infants with 23--24 weeks' gestation was included as an independent factor in the multivariate analyses of associated clinical factors for mortality and survival without major morbidities, it is possible that unknown confounders might not have been controlled in this retrospective study. However, although the consistency of any specific clinical management policies within each group was not controlled, the significantly higher antenatal steroid use and Apgar score at 5 min in group 1 suggests that evidence-based perinatal and neonatal intensive care practices were provided in group 1 than in group 2. This implies that this nationwide study was well placed for identifying clinical strategies associated with decreased mortality and survival without major morbidities of periviable EPT infants, which might also redeem the limitations of the study.

In conclusion, a reduced mortality rate of infants born at 23--24 weeks' gestation was accompanied by a significantly higher survival without major morbidities rate for the more mature infants with 25--26 weeks' gestation, which was mostly attributable to decreased incidences of major morbidities, including BPD, severe IVH, PVL, and LOS. Antenatal steroid use and Apgar score at 5 min were clinical factors associated with decreased mortality and survival without major morbidities of EPT infants. Collectively, clinical implementation of more aggressive perinatal and improved neonatal intensive care practices could simultaneously lead to decreased mortality and survival without major morbidities in periviable EPT infants.

Methods {#Sec7}
=======

Patients {#Sec8}
--------

The database registry of the KNN prospectively registered the clinical information of VLBWIs admitted to the 67 voluntarily participating NICUs covering \>80% of VLBWIs in Korea^[@CR12],[@CR21]^. The enrolment criteria of KNN is registering only VLBWIs actively resuscitated in the delivery room, and admitted to the NICU in this study. Resuscitating infants \>24 weeks' gestation is mandatory by law in Korea, but most Korean tertiary NICUs are currently willing to resuscitate infants up to 23 weeks' gestation. Trained staff used a standardised operating procedure to collect demographic and clinical information. Of the 8,287 VLBWIs born between January 1, 2013, and December 31, 2016, who were registered in the KNN, we collected data on 2,184 infants born at 23 weeks 0 days to 26 weeks 6 days of gestation. Forty ungrouped infants with 25--26 weeks' gestation registered from the 9 NICUs were excluded as there was no registry of infants with 23--24 weeks' gestation and we could not group these infants because of their lack of registry in the infants at 23--24 weeks' gestation; moreover, 61 infants with major congenital anomalies were excluded from the study. Fifty-six of the 67 participating NICUs which had policy of actively resuscitating infant at 23--24 weeks enrolled more than one infant with 23--24 weeks' gestation. We divided the units into two groups according to the (1) baseline mortality of the infants at 23--24 weeks' gestation in this study and (2) the baseline mortality of 50% of the infants at 23--24 weeks' gestation based on previous studies, which show that decreased mortality from 51% to 47% of infants at 23--24 weeks' gestation is associated with increased survival without major morbidity of more mature infants at 25--28 weeks' gestation (1). Given the wide institutional variation in the mortality rate of these infants, we divided all 2,083 infants with 23--26 weeks' gestation into two groups: group 1 included patients from centres with a ≤50% mortality rate for 23--24 weeks' gestation (1,074 patients from 24 hospitals) and group 2 included patients from centres with a \>50% mortality rate for 23--24 weeks' gestation (1,009 patients from 32 hospitals) (Figs [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). The infants were further stratified into those with 23--24 weeks' gestation (n = 398 from 24 NICUs and 322 from 32 NICUs for groups 1 and 2, respectively) and 25--26 weeks' gestation (n = 676 and 687 for groups 1 and 2, respectively).Figure 1The wide variability of the mortality rate among infants born at 23--24 weeks gestation from the Korean Neonatal Network included in this study.Figure 2Study population from the Korean Neonatal Network database.

We compared maternal and neonatal variables, including gestational age, birth weight, sex, antenatal corticosteroid use, chorioamnionitis, premature rupture of membranes (PROM), Apgar score at 1 and 5 min, hypertensive disorder of pregnancy, *in vitro* fertilisation, and body temperature at admission to the NICU, born inside or outside hospital between group 1 and 2 in the 23--24 and 25--26 weeks' gestation subgroups.

We also compared mortality rates and various major morbidities, including BPD, severe IVH, PVL, necrotising enterocolitis (NEC), retinopathy of prematurity (ROP), and LOS between groups 1 and 2 in the 23--24 and 25--26 weeks' gestation subgroups.

Definitions {#Sec9}
-----------

We complied a network database operation manual to define the patient characteristics. In the manual, gestational age was determined from the obstetric history based on the last menstrual period. Antenatal steroid use was defined as the administration of any corticosteroid to the mother at any time before delivery to accelerate foetal lung maturity. Chorioamnionitis was confirmed by placental pathology^[@CR22]^ and PROM was defined as rupture of membranes over 24 hours before the onset of labour. BPD was defined as the use of supplemental oxygen or respiratory support at 36 weeks' gestational age, corresponding to moderate to severe BPD using the severity-based definition for BPD of the National Institutes of Health consensus^[@CR23]^. Severe IVH was defined as grade 3 or 4 according to the classification of Papile *et al*.^[@CR24]^ PVL was defined as cystic PVL based on either head ultrasonography or cranial magnetic resonance imaging performed at ≥2 weeks of age. NEC was defined as ≥ stage 2b according to the modified Bell criteria^[@CR25]^. ROP was defined as ≥stage 3 during the NICU admission according to an international committee for the classification of ROP^[@CR26]^. LOS was defined by a positive blood culture obtained after postnatal day 7 in symptomatic infants suggestive of septicaemia and more than 5 days of antibiotic treatment. Survival without major morbidities was defined as survival without moderate to severe BPD, severe IVH, PVL, NEC, ROP, and LOS at the time of discharge.

Statistical analysis {#Sec10}
--------------------

The characteristics of the study participants and their prenatal and neonatal morbidities were described as the mean ± standard deviation (SD) for continuous variables and as numbers and proportions for binary for categorical variables. Unadjusted comparisons between the two groups were performed using the chi-square or Fisher's exact test for categorical data and the t-test for continuous data. Logistic regression was used to estimate the ORs with 95% CIs to identify the clinical factors between group 1 and group 2 associated with mortality and survival without major morbidities stratified by gestation age group. In multiple logistic regression, significantly different clinical factors associated with mortality and survival without major morbidities between group 1 and group 2 and previously known factors were adjusted. Models included covariates for gestational age, birth weight per 100 g, Apgar score 5 min, antenatal steroid use, delivery mode, histologic chorioamnionitis, and *in vitro* fertilisation. A *P*-value \< 0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 21 (IBM Corp., Chicago, IL, USA).
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